Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.
Ooki A, Morita S, Iwamoto S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Suto T, Hashiguchi Y, Yabuno T, Sakamoto J, Tsuji A, Ando M, Yamaguchi K.
Ooki A, et al. Among authors: yabuno t.
Cancer Med. 2020 Mar;9(5):1779-1789. doi: 10.1002/cam4.2826. Epub 2020 Jan 21.
Cancer Med. 2020.
PMID: 31962002
Free PMC article.
Clinical Trial.